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Introduction
It is now well-established that to fully understand the 
mechanism(s) driving tumor recurrence, metastasis and clinical 
outcome in cancer patients, it is necessary to study the role of 
the tumor microenvironment. In particular, cancer-associated 
fibroblasts play a crucial role through paracrine interactions with 
adjacent epithelial cancer cells.1
previous studies have demonstrated that loss of caveolin-1 (Cav-1) in stromal cells drives the activation of the TGFβ signaling, 
with increased transcription of TGFβ target genes, such as connective tissue growth factor (CTGF). In addition, loss of 
stromal Cav-1 results in the metabolic reprogramming of cancer-associated fibroblasts, with the induction of autophagy 
and glycolysis. However, it remains unknown if activation of the TGFβ/CTGF pathway regulates the metabolism of cancer-
associated fibroblasts. Therefore, we investigated whether CTGF modulates metabolism in the tumor microenvironment. 
For this purpose, CTGF was overexpressed in normal human fibroblasts or MDA-MB-231 breast cancer cells. Overexpression 
of CTGF induces HIF-1α-dependent metabolic alterations, with the induction of autophagy/mitophagy, senescence and 
glycolysis. Here, we show that CTGF exerts compartment-specific effects on tumorigenesis, depending on the cell-type. 
In a xenograft model, CTGF overexpressing fibroblasts promote the growth of co-injected MDA-MB-231 cells, without 
any increases in angiogenesis. Conversely, CTGF overexpression in MDA-MB-231 cells dramatically inhibits tumor growth 
in mice. Intriguingly, increased extracellular matrix deposition was seen in tumors with either fibroblast or MDA-MB-231 
overexpression of CTGF. Thus, the effects of CTGF expression on tumor formation are independent of its extracellular 
matrix function, but rather depend on its ability to activate catabolic metabolism. As such, CTGF-mediated induction 
of autophagy in fibroblasts supports tumor growth via the generation of recycled nutrients, whereas CTGF-mediated 
autophagy in breast cancer cells suppresses tumor growth, via tumor cell self-digestion. Our studies shed new light on 
the compartment-specific role of CTGF in mammary tumorigenesis, and provide novel insights into the mechanism(s) 
generating a lethal tumor microenvironment in patients lacking stromal Cav-1. As loss of Cav-1 is a stromal marker of 
poor clinical outcome in women with primary breast cancer, dissecting the downstream signaling effects of Cav-1 are 
important for understanding disease pathogenesis, and identifying novel therapeutic targets.
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We and others have recently shown that a loss of caveolin-1 
(Cav-1) in stromal cells is a predictor of early tumor recurrence, 
lymph node metastasis, tamoxifen resistance and poor clinical 
outcome in human breast cancer patients.2,3 To investigate the 
downstream effects of a loss of stromal Cav-1, we isolated bone 
marrow-derived stromal cells from WT and Cav-1(-/-)-null mice 
and subjected them to metabolomic and proteomic analyses and 
genome-wide transcriptional profiling. Interestingly, Cav-1(-/-) © 2012 Landes Bioscience.
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and autophagy in cancer-associated fibroblasts leads to cellular 
self-digestion, promoting the release of recycled nutrients into the 
tumor microenvironment, which can be used by adjacent cancer 
cells as building blocks to support their anabolic growth. In sup-
port of this hypothesis, we observed that in a xenograft model, 
the HIF-1α-dependent activation of autophagy in stromal cells 
greatly enhanced the tumorigenicity of MDA-MB-231 breast can-
cer cells. On the contrary, HIF-1α activation in MDA-MB-231 
cells suppressed tumor growth.8 As HIF-1α triggers autophagy in 
both fibroblasts and cancer cells, these data demonstrate that the 
role of autophagy in driving tumor formation is cell type- and 
compartment-specific.
Other studies have shown that a loss of Cav-1 in fibroblasts 
is sufficient to mediate the ligand-independent activation of 
transforming growth factorβ (TGFβ).1,7 TGFβ is activated dur-
ing normal wound repair9,10 and in fibrotic skin disorders.11,12 
TGFβ determines fibroblast proliferation, increases extracellu-
lar matrix deposition and can also induce a reduction of extra-
cellular matrix degradation.13 In a previous study of Cav-1(-/-) 
stromal cells, we demonstrated the upregulation of 35 transcripts 
associated with activated TGFβ signaling.14 In particular, one of 
the most upregulated TGFβ-target genes was connective tissue 
growth factor (CTGF), with a 2.2-fold induction.4 However, 
it remains unknown if CTGF plays a critical role in the tumor 
microenvironment.
CTGF is a TGFβ-target gene and a member of the CCN 
family of secreted proteins, which consists of four conserved sub-
domains: an insulin-like growth factor-binding protein (IGFBP) 
domain, a von Willebrand factor type C (VWC) domain, a 
thrombospondin type I (TSP) repeat and a C-terminal cysteine 
knot (CT) domain.15 CTGF is expressed in several cell types, 
such as endothelial cells, fibroblasts and leukocytes but espe-
cially in osteoblasts and chondrocytes. CTGF is a multi-func-
tional signaling modulator involved in a wide variety of biologic 
and pathologic processes, including cell proliferation, adhesion, 
migration and extracellular matrix synthesis. Furthermore, 
CTGF has been identified as a pro-mitogenic and pro-angio-
genic co-factor.9,16-19
While the role of CTGF in tissue fibrosis has been well stud-
ied,20 the function of CTGF in cancer pathogenesis remains con-
troversial. Interestingly, CTGF has been identified as an oncogene 
in a variety of cancer types but is considered a tumor-suppressor 
gene in other contexts. CTGF overexpression is found in mela-
noma, sarcoma, chondrosarcoma, acute lymphoblastic leukemia 
and pancreatic cancer21-25 and is associated with increased inva-
sion, migration, the desmoplastic reaction and with chemo-resis-
tance. However, other studies have shown that CTGF expression 
inhibits the migration and invasion of ovarian,26 colorectal27 and 
oral squamous cell28 carcinoma cells.
Thus, the aim of the present study was to evaluate the com-
partment-specific role of CTGF in breast cancer. In particular, 
we aimed to explore if CTGF plays a role in the metabolic repro-
gramming of both cancer cells and their tumor microenviron-
ment. To study the cell type- and compartment-specific effects of 
CTGF expression, CTGF was overexpressed in fibroblasts as well 
as in MDA-MB-231 breast cancer cells.
stromal cells showed significant metabolic alterations, with 
reprogramming toward glycolysis, induction of autophagy and 
oxidative stress.4 Indeed, acute knockdown of Cav-1 in fibroblasts 
induces the expression of pyruvate kinase M2 (PKM2), a glyco-
lytic enzyme sufficient to trigger aerobic glycolysis, and promotes 
the generation of reactive oxygen species (ROS).5 In addition, we 
demonstrated that a loss of stromal Cav-1 induces the transcrip-
tion of ROS-associated genes and of hypoxia-inducible factor 1α 
(HIF-1α) and NFκB target genes.5 Thus, a loss of Cav-1 in can-
cer-associated fibroblasts may favor tumor growth via oxidative 
stress and the stromal activation of HIF-1α and NFκB.6 In a 
co-culture system of normal fibroblasts and MCF7 breast cancer 
cells, we demonstrated that MCF7 cells induce ROS production 
and oxidative stress in adjacent fibroblasts, driving the activation 
of autophagy/mitophagy and aerobic glycolysis.5,7
The induction of autophagy/mitophagy and glycolysis in stro-
mal cells generates recycled nutrients to feed epithelial cancer 
cells. Then, increased lactate production derived from glycolysis 
fuels the mitochondrial metabolism of adjacent cancer cells, lead-
ing to high ATP generation in cancer cells and protection against 
cell death. The induction of the catabolic processes of mitophagy 
Figure 1. CTGF overexpression induces an autophagy/mitophagy pro-
gram in fibroblasts. (A) Fibroblasts were stably transfected with a CTGF 
or Lv-105 empty vector plasmid, using a lentiviral vector approach. Total 
proteins were isolated from transfected fibroblasts and analyzed by 
immunoblotting to confirm CTGF expression. (B) Immunoblot analysis 
shows that CTGF overexpression induces the activation of autophagy/
mitophagy in fibroblasts, as judged by increased expression levels of 
BNIp3, Beclin-1, Lamp-1 and LC3, as compared with control cells. The 
expression of β-actin was assessed to ensure equal protein loading.© 2012 Landes Bioscience.
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Results
CTGF overexpression in fibroblasts 
induces an autophagy/mitophagy 
program. Loss of stromal Cav-1 
drives oxidative stress and the 
induction of autophagy/mitophagy 
in the tumor stroma,5,7,29 leading to 
the generation of recycled nutrients 
that can be used by adjacent ana-
bolic epithelial cancer cells.5,29 We 
have previously demonstrated that 
a loss of stromal Cav-1 induces the 
ligand-independent activation of the 
TGFβ pathway7 and that Cav-1(-/-) 
stromal cells show the upregulation 
of 35 transcripts associated with 
activated TGFβ signaling, includ-
ing the TGFβ target gene CTGF.14
To investigate if CTGF plays a 
role in breast tumorigenesis, CTGF 
was stably overexpressed in stromal 
fibroblasts (Fig. 1A). Empty vec-
tor (Lv-105) control fibroblasts were generated in parallel. Then, 
CTGF overexpressing fibroblasts were analyzed by immunob-
lot blot analysis with a panel of autophagy/mitophagy markers. 
Figure 1B shows that CTGF overexpression induces the increased 
expression of LC3 and Beclin-1 (proteins involved in the forma-
tion and maturation of auto-phagosomes), Lamp-1 (a protein 
associated with auto-lysosomes and lysosomes) and BNIP3 (a 
mitophagy marker whose expression leads to reductions in mito-
chondrial mass and respiration).30 Therefore, CTGF expression 
is sufficient to induce autophagy and mitophagy in fibroblasts, 
downstream from a loss of stromal Cav-1.
CTGF overexpression in fibroblasts induces glycolysis. 
Increased BNIP3 expression downregulates mitochondrial mass 
and respiration by increasing the rate of mitophagy (mitochon-
drial autophagy), thus compromising ATP production.30 We 
speculated that CTGF-mediated increases in BNIP3 expression 
may lead to activation of glycolysis, to compensate for reduced 
mitochondrial function. Figure 2A shows that CTGF over-
expression drives elevated expression of lactate dehydrogenase 
(LDH) -A, -B and -C, the glycolytic enzymes that convert pyru-
vate into L-lactate. The induction of aerobic glycolysis was fur-
ther validated by the increased expression of Enolase 1, another 
enzyme in the glycolytic pathway.
To evaluate the functional role of increased expression of these 
glycolytic enzymes, we determined the L-lactate content of the 
fibroblast cell culture media. Figure 2B shows that CTGF fibro-
blasts display a significant 20% increase in overall L-lactate levels, 
as compared with control fibroblasts. Increased L-lactate produc-
tion in stromal cells could stimulate, by a paracrine mechanism, 
the conversion of lactate into pyruvate in adjacent breast cancer 
epithelial cells. Then, pyruvate would be used as a substrate for 
the TCA cycle to promote the oxidative mitochondrial activity 
of cancer cells.
Figure 2. Fibroblasts overexpressing CTGF show the induction of glycolysis. (A) Immunoblot analysis 
demonstrates that fibroblasts overexpressing CTGF display the increased expression of several enzymes 
involved in glycolysis (enolase-1, LDH-A, LDH-B and LDH-C), relative to empty vector control cells. β-actin 
was used to assess equal protein loading. (B) An L-lactate assay was performed on cell culture media to 
confirm the functional role of the increased expression of the glycolytic enzymes. In fibroblasts overex-
pressing CTGF, L-lactate production is significantly increased by 20%, as compared with the empty vector 
control.
Consistent with this “paracrine” metabolite hypothesis, we 
have previouosly shown that treatment with L-lactate is sufficient 
to induce mitochondrial biogenesis in breast cancer epithelial cells 
and can functionally enhance their metastastic potential.5,29,31,32
CTGF-induced activation of autophagy/mitophagy and gly-
colysis is HIF-1α-dependent. Our previous studies have dem-
onstrated that a loss of stromal Cav-1 causes an accumulation 
of ROS and the activation of HIF-1α, mimicking a constitutive 
pseudo-hypoxic state.14 It is well-established that increased ROS 
levels stabilize HIF-1α expression.33 In order to assess if CTGF 
overexpression in fibroblasts induces a pseudo-hypoxic condition, 
we first evaluated the expression of HIF-1α. Figure 3A shows 
that CTGF-overexpressing fibroblasts display increased levels of 
HIF-1α compared with control empty vector cells. In addition, 
a significant increase in ROS production was observed in fibro-
blasts overexpressing CTGF (Fig. 3B) relative to control cells, 
indicating that CTGF overexpression in fibroblasts does induce a 
“pseudo-hypoxic” state.
HIF-1α is a crucial transcription factor for the expression of 
glycolytic enzymes34 and autophagic proteins.35 To determine 
if the CTGF-mediated induction of glycolysis and autophagy 
is HIF-1α-dependent, fibroblasts overexpressing CTGF were 
treated with the HIF-1α inhibitor echinomycin. Echinomycin 
blocks the binding of HIF-1α to DNA, thereby inhibiting its tran-
scriptional action. Note that echinomycin treatment decreases 
HIF-1α expression (Fig. 4A) and greatly reduces the expression 
levels of autophagy (BNIP3, Lamp-1 and LC3, Fig. 4B) and 
glycolysis markers (Enolase 1, LDH-A and LDH-C, Fig. 4C). 
These results clearly indicate that the activation of autophagy, 
mitophagy and glycolysis in fibroblasts overexpressing CTGF is 
mediated by HIF-1α stabilization.
CTGF overexpression drives cellular senescence in fibro-
blasts. Several studies have reported that increased intracellular © 2012 Landes Bioscience.
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development, we employed a mouse xenograft model consisting 
of MDA-MB-231 breast cancer cells co-injected with CTGF or 
control fibroblasts in the flanks of nude mice. After 4 weeks, mice 
were sacrificed, and tumor weight and volume were measured. 
Remarkably, CTGF overexpression in fibroblasts induces an 
increase of 2-fold in tumor weight and of 2.6-fold in tumor vol-
ume, compared with control cells (Fig. 6A). Our previous stud-
ies have demonstrated that the autophagic stroma is sufficient to 
drive tumor development without increased neo-vascularization. 
Thus, we evaluated tumor vascularity using immuno-staining 
with antibodies directed against CD31. Figure 6B shows a sig-
nificant reduction of angiogenesis in CTGF tumors, indicating 
that CTGF favors breast cancer growth independently of angio-
genesis but more likely via the metabolic reprogramming of the 
tumor stroma.
It is well known that CTGF stimulates extracellular matrix 
deposition and activity.38,39 The extracellular matrix activates a 
variety of signals, which directly influence the growth, migration 
and differentiation of cells participating in virtually every state 
of breast cancer pathogenesis. To investigate if the extracellular 
matrix plays a key role in tumor development in our system, we 
next evaluated the expression of Type I Collagen and Tenascin C 
by immunohistochemistry in tumor xenografts. As predicted, the 
expression levels of both Type I Collagen and Tenascin C were 
elevated in tumors grown in the presence of CTGF-expressing 
fibroblasts, as compared with tumors grown with vector-alone 
control fibroblasts (Fig. 6C). These data suggest that CTGF 
could also favor tumor growth via the induction of extracellular 
matrix deposition.
CTGF-activated fibroblasts increase the mitochondrial 
activity of adjacent MDA-MB-231 cells. To experimentally 
evaluate if increased lactate production in fibroblasts stimu-
lates the mitochondrial metabolism of adjacent cancer epi-
thelial cells, we evaluated the expression of ATPase-Inibitor 
Factor 1 (ATPase-IF1) in a co-culture system of fibroblasts and 
MDA-MB-231 cells. ATPase-IF1 is an endogenous inhibitor of 
the mitochondrial ATP synthase, leading to reduced mitochon-
drial activity. It is known that silencing of ATPase-IF1 activates 
oxidative phosphorylation. Figure 7 shows that ATPase-IF1 
expression is decreased in MDA-MB-231 cells co-cultured 
with CTGF fibroblasts, as compared with MDA-MB-231 cells 
grown with control fibroblasts. These results indicate that CTGF 
expression in fibroblasts stimulates the mitochondrial activity of 
adjacent cancer cells, in a paracrine way, likely via the generation 
of high L-lactate levels.
MDA-MB-231 cells overexpressing CTGF show an increase 
in autophagy and oxidative stress. To evaluate if the role of 
CTGF in tumorigenesis is compartment-specific, we overex-
pressed CTGF in MDA-MB-231 cells (Fig. 8A). We next inves-
tigated whether CTGF also induces autophagy/mitophagy in 
epithelial cancer cells. Immunoblot analysis demonstrated that 
MDA-MB-231 cells overexpressing CTGF show the upregula-
tion of several autophagy/mitophagy markers under basal con-
dition (BNIP3, Lamp-1 and cathepsin B) (Fig. 8B) or upon 
nutrient-starvation (Beclin-1 and LC3) (Fig. 8C), indicating that 
CTGF can activate autophagy also in breast cancer epithelial 
ROS is involved in induction of senescence. In addition, recent 
evidence suggests that autophagy may also mediate the acquisi-
tion of a senescent phenotype.36,37 To verify if CTGF expression 
induces a senescent phenotype in fibroblasts, we next analyzed 
the expression of genes implicated in senescence by immunob-
lotting. Figure 5A shows that CTGF overexpression drives the 
upregulation of p21(WAF/CIP1) and p16(INK4A), both induc-
ers of cell cycle arrest. However, no changes were observed in 
p19(ARF) protein expression. Conversely, CTGF induces an 
increase of Cyclin D1 expression, likely a compensatory response 
to senescence. To independently assess if CTGF induces a senes-
cent phenotype, we next performed a β-galactosidase (β-Gal) 
activity assay by flow cytometry (Fig. 5B) and a β-Gal staining 
assay (Fig. 5C). Figure 5B shows that CTGF expression increases 
β-Gal activity, as judged by increased numbers β-Gal-positive 
cells and increased mean intensity. Similarly, conventional β-Gal 
staining is augmented in CTGF fibroblasts as compared with 
control fibroblasts (Fig. 5C), confirming the ability of CTGF to 
trigger a senescence phenotype.
CTGF overexpression in fibroblasts increases breast can-
cer growth independently of angiogenesis. To evaluate if 
CTGF expression in fibroblasts plays a role in breast cancer 
Figure 3. CTGF overexpression in fibroblasts induces a pseudo-hypoxic 
phenotype. (A) CTGF- and Lv-105 fibroblasts were analyzed by im-
munoblotting with antibodies against HIF-1α. Note that HIF-1α levels 
are augmented in CTGF fibroblasts, suggesting that CTGF induces a 
pseudo-hypoxic state. Two different exposures are shown. β-actin was 
used to assess equal protein loading. (B) To evaluate if CTGF expression 
drives oxidative stress, we performed a ROS assay. CTGF overexpression 
induces a 20% increase in ROS production, as compared with control 
cells. p < 0.05.© 2012 Landes Bioscience.
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Discussion
Previous studies have demonstrated that a loss of Cav-1 in stromal 
cells induces the ligand-independent activation of the TGFβ path-
way,7,40-42 with the increased transcription of the TGFβ target gene 
CTGF.1,4,14,43 It is now well known that CTGF induces tissue fibro-
sis, and that alterations in the extracellular matrix influence tumor 
growth and clinical outcome.21,44 It has also been demonstrated 
cells. However, no changes in L-lactate production were observed 
in MDA-MB-231 cells overexpressing CTGF (data not shown).
Since we demonstrated that CTGF induces autophagy in fibro-
blasts via HIF-1α (Fig. 3), we evaluated if the same mechanism 
operates in MDA-MB-231 cells. Although HIF-1α expression 
is only slightly increased in MDA-MB-231 cells overexpressing 
CTGF (Fig. 8D), a significant 20% increase in ROS production 
in MDA-MB-231 cells overexpressing CTGF was observed as 
compared with control cells (Fig. 8E). Therefore, we believe that 
the CTGF induction of autophagy also depends on increased oxi-
dative stress in breast cancer cells. Thus, we conclude that CTGF 
induces an autophagic program in both cell types, fibroblasts and 
MDA-MB-231 cells, by inducing oxidative stress, HIF-1α activa-
tion and a “pseudo-hypoxic” phenotype.
CTGF overexpression does not modulate the expression of 
senescence markers in breast cancer cells. In order to under-
stand if CTGF activate the same processes activated in fibroblasts 
in epithelial breast cancer cells, we evaluated the expression of 
proteins involved in cell cycle regulation. Figure 9 demonstrates 
that CTGF overexpression in MDA-MB-231 cells does not 
induce markers of senescence. Indeed, no significant changes 
were detected in p16(INK4A), p19(ARF) and Cyclin D1 expres-
sion levels, whereas p21(WAF1/CIP1) was undetectable.
CTGF overexpression in breast cancer cells inhibits tumor 
growth. To investigate the effects of CTGF overexpression in 
breast cancer cells in vivo, CTGF-MDA-MB-231 and control 
MDA-MB-231 cells were injected into the flanks of athymic 
nude mice. Surprisingly, Figure 10A shows that after 3 weeks, 
CTGF overexpression caused a nearly 3-fold reduction in tumor 
growth. Also in this context, we did not detect any differences 
in tumor neo-vascularization, as assessed by quantification of 
CD31-positive vessels (Fig. 10B). These results clearly indicate 
that CTGF plays a compartment- and cell type-specific role dur-
ing tumor formation and exerts opposing effects depending on 
which cell type expresses it.
Finally, to evaluate the role of extracellular matrix deposition 
in CTGF-mediated tumorigenesis, we evaluated the expression of 
Type I Collagen and Tenascin C in MDA-MB-231 tumor xeno-
grafts. Interestingly, the expression levels of Type I Collagen and 
Tenascin C are increased in tumors formed by MDA-MB-231 
cells overexpressing CTGF, relative to control tumors (Fig. 10C). 
These results indicate that in our model, the role of CTGF in 
tumorigenesis is independent on its role in extracellular matrix 
remodeling. In fact, we observed increased extracellular matrix 
deposition in tumors both when CTGF was expressed by cancer 
cells and by fibroblasts, despite the fact that the CTGF effects on 
tumor growth are just the opposite.
Thus, we speculate that in our experimental system, CTGF’s 
effects are likely due to its intracellular action and not to its 
extracellular action. The cells overexpressing CTGF undergo 
metabolic reprogramming and become more autophagic. The 
induction of CTGF-mediated autophagy in epithelial tumor 
cells will cause self-digestion and inhibition of tumor growth. 
Conversely, the induction of CTGF-mediated autophagy in 
tumor fibroblasts will generate building blocks for the anabolic 
growth of cancer cells.
Figure 4. The activation of autophagy and glycolysis in CTGF fibro-
blasts is HIF-1α-dependent. To evaluate if the activation of autophagy 
and glycolysis of CTGF fibroblasts is HIF-1α dependent, CTGF fibroblasts 
were treated with the HIF-1α inhibitor echinomycin (5–10 ng/ml) or 
vehicle alone (DMSO) for 24 h. Western blot analysis demonstrates that 
echinomycin treatment reduces the expression of (A) HIF-1α, (B) mi-
tophagy (BNIp3) and autophagy (Lamp-1 and LC3) markers, and (C) gly-
colytic enzymes (enolase 1, LDH-A and LDH-C). equal loading control 
was assessed using β-actin. These results indicate that CTGF expression 
enhances autophagy/mitophagy and glycolysis in a HIF-1α-dependent 
manner.© 2012 Landes Bioscience.
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study if the cell type-specific expression of CTGF differentially 
affects tumor development.
The role of CTGF in breast cancer remains controversial. 
Elevated CTGF mRNA levels were found in human invasive 
ductal carcinomas and mouse mammary tumors and were con-
fined to the fibrous tumor stroma.44 In another breast cancer 
study, overexpression of CTGF was positively associated with age, 
tumor size, stage and lymph node metastasis.45 Mechanistically, 
that a loss of stromal Cav-1 induces the metabolic reprogramming 
of cancer-associated fibroblasts with the induction of glycolysis and 
autophagy. However, it remains unknown if the activation of the 
TGFβ/CTGF pathway plays a role in the metabolic reprogram-
ming of stromal cells induced by a loss of stromal Cav-1.
Therefore, the purpose of this study was to investigate if the 
TGFβ-target gene CTGF plays a role in the metabolic remodel-
ing of the tumor microenvironment. In particular, we aimed to 
Figure 5. CTGF overexpression in fibroblasts induces a senescence phenotype. (A) Immunoblot analysis performed on control and CTGF overexpress-
ing fibroblasts demonstrates that CTGF expression induces the upregulation of p21 (CIp1/WAF1) and of p16Ink4A, both inhibitors of cell cycle progres-
sion. No changes were detected for p19 expression levels. Conversely, CTGF expression also induces the upregulation of cyclin D1, probably as a 
compensatory response against senescence. equal loading was assessed using β-actin. (B) A β-galactosidase assay was performed by FACS analysis 
on control and CTGF overexpressing fibroblasts. The number of β-Galactosidase-positive cells (left) and the β-galactosidase intensity mean (right) are 
both increased in CTGF overexpressing fibroblasts. (C) Conventional β-galactosidase staining was also performed on control and CTGF overexpressing 
fibroblasts to independently confirm that CTGF overexpression induces senescence. Note that CTGF fibroblasts have intense blue staining, indicative 
of increased β-galactosidase activity.© 2012 Landes Bioscience.
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and breast cancer cells. Thus, CTGF-induced autophagy in 
fibroblasts can drive stromal cell digestion, leading to the release 
of chemical building blocks into the tumor microenvironment. 
These nutrients could be used as fuel for the anabolic growth of 
breast cancer cells, driving increased tumor mass independently 
of angiogenesis. Furthermore, we show that CTGF overexpres-
sion in stromal cells triggers the induction of glycolysis. The final 
product of glycolysis, L-lactate, could act in a paracrine way on 
breast cancer cells. Increased L-lactate uptake by breast cancer 
cells could activate LDH in cancer cells. At high lactate concen-
trations, LDH converts L-lactate into pyruvate, which is a sub-
strate of the Krebs cycle, driving an increase in mitochondrial 
metabolic activity. Consistent with this hypothesis, we detected 
reductions in ATPase-IF1 expression in MDA-MB-231 cells 
co-cultured with CTGF fibroblasts compared with the control 
fibroblasts. Mechanistically, we show that the CTGF-mediated 
induction of autophagy occurs via increased oxidative stress and 
HIF-1α stabilization. Our results are consistent with previous 
the tumor-promoting role of CTGF is supported by data showing 
that CTGF enhances tumor cell migration and angiogenesis46 
and confers drug resistance.47,48 Conversely, other studies have 
indicated that CTGF may act as a tumor suppressor and have   
reported that low levels of CTGF are associated with increased 
metastasis and poor prognosis in breast cancer patients.49 For 
example, Hishikawa et al. demonstrated that forced overexpres-
sion of CTGF in MCF7 cells induces apoptosis.50
In our current studies, we propose a novel viewpoint to explain 
the controversial role of CTGF in breast cancer. Our data clearly 
indicate that CTGF exerts compartment-specific actions, and 
that its effects on tumor growth are opposite depending on the 
cell type producing CTGF. In fact, surprisingly, overexpression 
of CTGF in breast cancer epithelial cells inhibits tumor growth, 
but the opposite, tumor-promoting effect was observed when 
CTGF is overexpressed in the tumor fibroblast compartment.
We show for the first time that the overexpression of CTGF 
drives the induction of autophagy in both cell types, fibroblasts 
Figure 6. CTGF overexpression in fibroblasts promotes tumor growth. To evaluate the effects of CTGF on tumor development in vivo, CTGF fibroblasts 
or control fibroblasts were co-injected with MDA-MB-231 cells subcutaneously in nude mice. (A) The xenograft model shows that fibroblasts overex-
pressing CTGF promote tumor growth, as demonstrated by increased tumor weight and tumor volume (respectively 2 and 2.6-fold), compared with 
Lv-105 control fibroblasts. n = 10; p-values are as indicated. (B) To investigate if CTGF promotes angiogenesis, tumor xenografts were immuno-stained 
with CD31 antibodies. Surprisingly, quantification of CD31-positive vessels reveals a significant reduction in angiogenesis in CTFG-tumors, indicating 
that CTGF stimulates tumor growth independently of angiogenesis. (C) To evaluate the role of extracellular matrix deposition in the CTGF-mediated 
tumor growth, we performed immunohistochemistry analysis on tumor xenografts with antibodies against Type I Collagen and Tenascin C. Note that 
tumors with CTGF-overexpressing fibroblasts show higher levels of Type I Collagen and Tenascin C.© 2012 Landes Bioscience.
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homolog of the yeast ATG1 is essential for the initial building 
of the autophagosome, is highly expressed in senescent cells, 
and that ULK-3 overexpression induces autophagy and senes-
cence. Furthermore, the knockdown of ATG5 or ATG7 reduces 
β-galactosidase activity, the most widely used marker of senes-
cence.37 Inhibition of autophagy delays the senescence pheno-
type. Thus, the induction of autophagy in fibroblasts promotes 
the acquisition of the senescent phenotype.37 Recently, a new 
mechanism by which autophagy can lead to pre-mature senes-
cence, has been proposed. Goligorsky et al. have demonstrated 
that stress-induced lysosomal membrane permeabilization drives 
the release of cathepsin B in the cytosol. Cathepsin B is a lyso-
somal cysteine protease, which induces SIRT1 depletion leading 
to autophagy-induced premature senescence.36 Thus, autophagy 
and senescence may be part of the same physiological process, 
known as the autophagy-senescence transition (AST) (Fig. 11).
Cellular senescence is a reversible process that limits prolifera-
tion of cells at risk for neoplastic transformation and contributes 
to aging.53-56 On the other hand, although the mechanisms have 
not been fully elucidated yet but are likely to contrast aging, the 
induction of senescence leads to the secretion of several mitogenic 
substances, including growth factors, cytokines and extracellular 
matrix components,53,57 that alter the tumor microenvironment 
and favor tumor growth.58
In our study, we show for the first time that CTGF has the 
ability to induce senescence. Interestingly, CTGF-mediated 
induction of senescence is cell-type specific, as it occurs only in 
fibroblasts but not in breast cancer cells. It might be that the induc-
tion of senescence in fibroblasts could constitute an additional 
mechanism through which CTGF overexpression in stromal cells 
drives tumor growth. Although the molecular mechanism(s) that 
link autophagy with senescence are still unclear, we propose that 
systemic induction of autophagy and increased protein turnover 
could lead stromal cells to establish a senescent-like phenotype to 
protect them from further self-digestion.
Our results indicate that the tumor-promoting effects of 
CTGF may be independent of its well-known role in extracellular 
matrix remodeling. We unexpectedly observed that CTGF has 
opposite effects when it is produced by stromal cells or by breast 
cancer cells. This suggests that the CTGF effects are not due 
to its extracellular secretion; otherwise, we should observe the 
same results, independently of the cell type producing CTGF. 
Thus, our data clearly indicate that CTGF acts via an intra-
cellular mechanism, likely through the metabolic reprogram-
ming of the CTGF-producing cells. In support of this notion, 
we observed increased extracellular matrix deposition in tumor 
xenografts generated by CTGF-MDA-MB-231 cells and by 
CTGF-fibroblasts. Indeed, we observed increased extracellular 
matrix, which is usually considered a marker of tumor aggres-
siveness, in the CTGF-MDA-MB-231 xenogafts as well when the 
tumor mass was reduced. These data demonstrate that CTGF 
can still be secreted, but that the main CTGF tumor-promoting 
effects are due to its ability to drive metabolic reprogramming 
within cells. This is the first time that CTGF has been shown to 
modulate the metabolic status of stromal cells within the tumor 
microenvironment.
studies showing that CTGF induces HIF-1α upregulation.51 
However, the mechanism(s) by which CTGF induces HIF-1α 
activation is currently unknown.
Conversely, we show that forced CTGF overexpression in 
breast cancer cells inhibits tumor growth. We demonstrate that 
CTGF overexpression in epithelial breast cancer cells induces 
autophagy. Activation of autophagy in cancer cells increases 
tumor cell self-digestion, with a consequent decrease in tumor 
mass. Mechanistically, we propose that CTGF overexpression 
leads to increased oxidative stress, which, in turn, stabilizes 
HIF-1α. In fact, we have previously demonstrated that HIF-1α 
activation in breast cancer cells drives the induction of autophagy 
and inhibits tumor growth.8
Several studies have reported that increased intracellular ROS 
is involved in the induction of senescence. Two mechanisms have 
been proposed to explain ROS action on senescence. The first 
possibility is that ROS can lead to random damage to cellular 
components, thus acting as a non-specific senescence media-
tor. For example, an increase in ROS levels causes DNA dam-
age, leading to activation of p53, which, in turn, drives cell cycle 
arrest via induction of p21. The second explanation is that ROS 
can function as messenger molecules that activate specific redox-
dependent targets, and those could induce senescence.52
Recent evidence also links autophagy to cellular senescence. 
In particular, it has been demonstrated that ULK-3, the human 
Figure 7. CTGF fibroblasts greatly decrease the expression of ATpase-
IF1 in adjacent MDA-MB-231 cells. To verify if CTGF fibroblasts exert 
any paracrine effects on tumor cells, GFp-positive MDA-MB-231 cells 
were co-cultured with CTGF fibroblasts or control fibroblasts for 3 d. 
Cells were then immuno-stained with antibodies against ATpase-IF1 (an 
endogenous inhibitor of the mitochondrial ATp synthase, ReD). Nuclei 
were stained with DApI (BLUe). Note that fibroblasts overexpressing 
CTGF reduce the levels of ATpase-IF in adjacent MDA-MB-231 cells (GFp). 
The white stars mark the nuclei of MDA-MB-231 cells. These results 
indicate that CTGF fibroblasts increase the mitochondrial activity in 
adjacent breast cancer cells, by reducing ATpase-IF expression.© 2012 Landes Bioscience.
Do not distribute.
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with protease (Roche Diagnostics) and phosphatase (Sigma) 
inhibitor cocktails. After rotating for 40 min, samples were cen-
trifuged 10 min at 13,000x g at 4°C, and the supernatants were 
collected. For nuclear proteins, RIPA buffer (50 mM TRIS-HCl 
In conclusion, we propose a new compartment-specific role 
for CTGF in tumor formation, which is mediated via intracel-
lular metabolic rearrangements. The overexpression of CTGF 
in breast cancer epithelial cells leads to autophagy activation, 
tumor cell digestion and inhibition of tumor growth. On the 
other hand, overexpression of CTGF in fibroblasts similarly 
drives the induction of autophagy, but in this case, enhances 
the release of recycled chemical building blocks into the tumor 
microenvironment, which can be used as “fuel” by anabolic 
tumor cells. Finally, the overexpression of CTGF drives a senes-
cence phenotype in fibroblasts, which may further promote 
tumor growth.
Materials and Methods
Materials. Antibodies were as follow: CTGF (6B13) (Santa 
Cruz, sc-101586); β-Actin, (Sigma-Aldrich, A5441); Beclin-1 
(Novus Biologicals, NBP1-00085); BNIP3 (Abcam, ab10433); 
Cathepsin B (FL-339) (Santa Cruz, sc-13985); Lamp-1 (E-5) 
(Santa Cruz, sc-17768); LC3 (Abcam, ab48395); Enolase 1 
(Cell Signaling, 3810); LDH-A (Cell Signaling, 2012); LDH-B 
(Sigma-Aldrich, AV48210); LDH-C (Sigma-Aldrich, AV53602); 
HIF-1α, (BD Transduction Laboratories, 610959); p21 (H-164) 
(Santa Cruz, sc-756); p19 (DCS-240) (Santa Cruz, sc-53639); 
p16 (H-156) (Santa Cruz, sc-759); cyclin D1 (Thermo Scientific, 
MS-210); ATPase-IF1 (Abcam, ab811061); Tenascin C (Leica 
Microsystems, NCL-TENAS-C); and Type-I-Collagen (Cell 
Sciences, PS065).
Cell culture. GFP-positive MDA-MB-231 breast cancer 
cells (gift of Dr. Fatatis, Drexel University) and human foreskin 
immortalized fibroblast (hTERT-BJ1, Clontech) were grown in 
DMEM supplemented with 10% fetal bovine serum (FBS) and 
PS (100 units/mL penicillin, 100 μg/mL streptomycin). Cells 
were maintained at 37°C, in a 5% CO2 incubator. Starvation 
was performed using Hank’s Balanced salt solution (HBSS) 
supplemented with 40 mM Hepes and 1% PS. For the echino-
mycin-related experiments, cells were treated with 5 or 10 ng/ml 
echinomycin (Enzo life Sciences) dissolved in DMSO for 24 h. 
For co-culture experiments, fibroblasts and MDA-MB-231 cells 
were plated at a ratio 5:1 on glass coverslips in 12-well plates in 
complete media. After 24 h, the media was changed to DMEM 
with 10% NuSerum (BD Biosciences). Cells were maintained in 
co-culture for 3 d.
Lenti-viruses. Lentiviral plasmids, packaging cells and 
reagents were from Genecopoeia. Lenti-viruses were prepared by 
transfection of 293Ta packaging cells. For this purpose, 1.7 mil-
lion 293Ta cells were seeded in 10-cm plates. After 48 h, 293Ta 
cells were transfected with the lentiviral plasmids EX-NEG-Lv105 
(Empty Vector) and EX-A0312-Lv105 (encoding CTGF) using 
EndoFectin. After 48 h, the viruses were collected, centrifuged 
and filtered. Target cells (fibroblasts or MDA-MB-231 cells) 
were infected with the viruses and then selected with puromycin 
(1.5 μg/ml for fibroblasts and 2 μg/ml for MDA-MB-231 cells).
Immunoblot analysis. Cells were scraped into lysis buf-
fer containing 10 mM TRIS-HCl pH 7.5, 150 mM NaCl, 
1% Triton X-100 and 60 mM N-octyl-glucoside supplemented 
Figure 8. MDA-MB-231 cells overexpressing CTGF display the induction 
of autophagy/mitophagy, with HIF-1α activation. To study if CTGF ex-
pression has any compartment-specific effects, CTGF was overexpressed 
in MDA-MB-231 cells. (A) Immunoblot analysis was performed on total 
protein lysates to confirm CTGF overexpression. (B and C) MDA-MB-231 
cells overexpressing CTGF show activation of an autophagy/mitophagy 
program. Immunoblot analysis on CTGF- and control-MDA-MB-231 
cells reveals that CTGF significantly increases the expression levels of 
several proteins involved in mitophagy (BNIp3) and autophagy (Lamp-1, 
Beclin-1, cathepsin B and LC3) under (B) basal condition or (C) after 2 h 
of nutrient starvation. (D) Immunblot analysis of total protein lysates 
from control and CTGF-MDA-MB-231 cells shows that CTGF expression 
induces the activation of HIF-1α in MDA-MB-231 cells. Two exposures 
are shown. For all, β-actin was used as control for equal protein load-
ing. (e) ROS assay performed on control- and CTGF-MDA-MB-231 cells 
reveals that CTGF expression induces a 20% increase in ROS production.© 2012 Landes Bioscience.
Do not distribute.
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pH 7.5, 150mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 
0.1% SDS plus protease and phosphatase inhibitors) was used. 
After lysis, cells were sonicated and centrifuged at 12,000x g for 
10 min at 4°C to pellet insoluble debris. Protein concentrations 
were evaluated with BCA kit (Pierce). To detect HIF-1α, cells 
were lysed in Urea Buffer (6.7 M urea, 10% glycerol, 1% SDS, 
10 mM TRIS-HCl pH 6.6, 1% Triton X-100 containing protease 
and phosphatase inhibitors). Cells were homogenized, incubated 
on ice for 10 min and centrifuged at 12,000x g for 10 min at 4°C. 
Protein content was determined by Bradford assay (BioRad). 
Proteins were separated by SDS-PAGE (10 to 15% acrylamide) 
and transferred to a nitrocellulose membrane. After blocking in 
5% milk, membranes were incubated with primary antibodies, 
followed by incubation with peroxidase-coupled secondary anti-
bodies. Bound antibodies were detected using enhanced chemi-
luminescence substrate (Thermo Scientific).
Lactate assay. 105 cells were plated into 12-well plates in 
complete media. After 24 h, the media was changed to DMEM 
containing 2% FBS. After 48 h, the media was collected, and 
the lactate concentration was measured using the EnzyChromTM 
L-Lactate Assay Kit (cat #ECLC-100, BioAssay Systems) accord-
ing to the manufacturer’s instructions. The L-lactate concentra-
tion was normalized to the cellular protein content per well.
ROS assay. Cells were seeded in 12-well plates in complete 
media. The next day, the media was changed to DMEM contain-
ing 10% NuSerum and 1% PS. ROS assay was performed after 
48 h. Fibroblasts were incubated with 10 μM CM-H2DCFDA 
(Invitrogen, C6827) for 15 min at 37°C. Then, cells were washed 
with PBS and incubated in complete media for 15 min at 37°C. 
GFP-positive MDA-MB-231 cells were incubated with CellROX 
Deep Red Reagent (Invitrogen, C10422) at a final concentration 
of 5 μM in complete media for 30 min at 37°C. To evaluate ROS 
content, cells were washed, trypsined, resuspended in HBSS and 
analyzed by flow-cytometry.
Figure 9. Overexpression of CTGF in MDA-MB-231 does not induce 
senescence. protein lysates from Lv-105 and CTGF-MDA-MB-231 cells 
were analyzed by immunoblotting with antibodies against cell cycle 
proteins. No differences in p16, p19 and cyclin D1 expression levels were 
detected, while p21 was undetectable. β-actin was used as control for 
equal loading.
Figure 10. CTGF overexpression in breast cancer cells inhibits tumor 
growth. (A) Lv-105- and CTGF-MDA-MB-231 cells were injected subcu-
taneously in nude mice. Tumors were then harvested after 3 weeks. 
Surprisingly, CTGF overexpression in MDA-MB-231 cells induces a nearly 
3-fold reduction in tumor growth, as compared with empty vector 
controls. n = 10, p-values are as indicated. (B) CD31 staining and quanti-
fication on tumor xenografts shows no differences in tumor neo-vascu-
larization. (C) Tumor xenografts were immunostained with antibodies 
against Type I Collagen and Tenascin C. Interestingly, the expression of 
Type I Collagen and Tenascin C are greatly increased in MDA-MB-231 
tumors with CTGF overexpression, although tumor size is decreased.© 2012 Landes Bioscience.
Do not distribute.
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pH 6.0 for 10 min using a pressure cooker. After blocking with 
3% hydrogen peroxide for 10 min, sections were incubated with 
10% goat serum for 1 h. Then, sections were incubated with 
primary antibodies overnight at 4°C. Antibody binding was 
detected using a biotinylated secondary (Vector Labs) followed 
by strepavidin-HRP (Dako). Immunoreactivity was revealed 
using 3,3'-diaminobenzidine. Finally, samples were counter-
stained with hematoxylin, dehydrated, mounted and observed 
under the microscope.
Immunofluorescence. Cells were fixed with 2% PFA for 
30 min, rinsed and permeabilized with 0.1% Triton X-100, 
0.2% BSA in PBS for 10 min. To quench free aldehyde groups, 
cells were incubated with 25 mmol/L NH4Cl in PBS for 10 min. 
Then, cells were rinsed with PBS, incubated with ATPase-IF1 
antibodies, followed by fluorescently labeled secondary antibod-
ies. Samples were incubated with DAPI, mounted and analyzed 
using a confocal microscope.
Statistical analysis. Data were analyzed with the Student 
t-test. p-values lower than 0.05 were considered statistically 
significant.
Disclosure of Potential Conflicts of Interest 
No potential conflicts of interest were disclosed.
Senescence-associated  β-galactosidase staining. To detect 
β-galactosidase, the senescence β-Galactosidase Staining Kit 
(Cell Signaling 9860) was used. Cells were plated into 6-well 
plates in complete media; after 24 h, the media was changed to 
DMEM 10% NuSerum. After 48 h, cells were washed with PBS 
and fixed for 15 min at room temperature with fixative solution 
(2% formaldehyde, 0.2% glutaraldehyde in PBS). Afterwards, 
cells were washed two times with PBS and incubated over night 
at 37°C in a dry incubator without CO2 with the β-galactosidase 
staining solution. Then, cells were observed under a microscope.
Senescence-associated  β-galactosidase activity by flow 
cytometry. The senescence β-Galactosidase Activity Kit 
(Invitrogen, F1930) was used according to the manufacturer’s 
instructions. Briefly, cells were seeded in 6-well plates in DMEM 
supplemented with 10% FBS and 1% PS. After 24 h, the media 
was changed to DMEM with 10% NuSerum. After 48 h, cells 
were trypsinezed, centrifuged and counted. Then, cells were resus-
pended with staining media to obtain 107 cells/mL, and 100 μl 
of samples were transferred to flow cytometer tubes and placed 
on ice. 100 μl of pre-warmed FDG solution (2 mM Fluorescein 
β-D-galactopyranoside) was added to the pre-warmed cells. 
Tubes were placed in the 37°C water bath for exactly 1 min. The 
reaction was stopped by adding ice-cold staining media. Cells 
were analyzed by flow cytometry.
Animal studies. All in vivo studies were performed under 
National Institutes of Health (NIH) guidelines and were 
approved by the Institutional Animal Care and Use Committee 
(IACUC) of Thomas Jefferson University. Briefly, CTGF fibro-
blasts or control fibroblasts (300,000 cells)  were co-injected with 
MDA-MB-231 (1 million cells) in the flanks of athymic NCr 
nude mice (NCRNU; Taconic Farms; 6–8 weeks of age). In other 
experiments, CTGF-MDA-MB-231 or control MDA-MB-231 
(1 million cells) were injected in the flank of nude mice. Tumor 
size and weight was recorded over a 2–4 week period. Tumors 
were dissected out to determine weight and size using calipers. 
Tumor volume was calculated using the formula (x2y)/2, where 
x and y are the short and long tumor dimensions, respectively. 
Tumors were either fixed with 10% formalin or flash-frozen in 
liquid nitrogen-cooled isopentane.
Quantification of tumor angiogenesis. Six μm tumor fro-
zen sections were fixed with 4% paraformaldehyde in PBS for 
10 min at 4°C and washed three times with PBS. A three-step 
biotin-streptavidin-horseradish peroxidase method was used for 
antibody detection. After fixation, the sections were blocked with 
10% rabbit serum and incubated overnight at 4°C with rat mono-
clonal CD31 antibody (550274, BD Biosciences). The sections 
were then incubated with biotinylated rabbit anti-rat IgG (Vector 
Labs) and streptavidin-HRP (Dako). Immunoreactivity was 
revealed with 3,3'-diaminobenzidine. For quantitation of vessels, 
CD31-positive vessels were counted in 8–10 fields within the cen-
tral area of each tumor using a 20x objective lens and an ocular 
grid (0.25 mm2 per field). The total numbers of vessel per unit 
area was calculated, and the data was represented graphically.
Immunohistochemistry. Formalin-fixed paraffin-embedded 
tumor sections were de-paraffinized, rehydrated and washed in 
PBS. Antigen retrieval was performed in 10 mM sodium citrate, 
Figure 11. CTGF drives the autophagy-senescence transition (AST) in 
cancer-associated fibroblasts. Here, we show that activation of TGFβ 
signaling, via CTGF expression in normal fibroblasts, is sufficient to con-
fer the cancer-associated fibroblast phenotype. Briefly, CTGF expression 
in stromal fibroblasts leads to ROS production, resulting in the stabiliza-
tion of the HIF1-transcription factor. HIF1-activation then promotes the 
induction of autophagy, mitophagy and glycolysis. Autophagy drives 
the onset of senescence, via the autophagy-senescence transition 
(AST), resulting in the upregulation of CDK-inhibitors [p21(WAF1/CIp1) 
and p16(INK4A)] as well as β-galactosidase (a lysosomal enzyme and 
marker of senescence). Oxidative stress, autophagy and senescence 
may also contribute to CTGF-induced fibrosis and extracellular matrix 
(eCM) remodeling.© 2012 Landes Bioscience.
Do not distribute.
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